ACT-02 / Accure Therap - LARVOL DELTA

Accure Therapeutics awarded a total of $1.6M in grants from The Michael J. Fox Foundation and Fonds National de Recherche de Luxembourg to bring first-in-class drug for Parkinson’s disease to clinical trials (Firstwordpharma Press Release) - "Accure Therapeutics...announces its receipt of two grants totalling $1.6M for two separate development programs on its drug candidate ACT-02....An MJFF grant to fund the phase I IND study in 2026. Accure Therapeutics received a $1.12M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The foundation is committed to finding a cure for Parkinson’s disease and developing improved therapies to enhance patients’ lives. The grant will fund the project titled ‘ACT-02 as a disease-modifying therapy for Parkinson’s (MJFF-025939)’....Funding will be used to finalize the preclinical activities required for completing investigational new drug (IND) studies, with a view to filing an application for a phase I IND study in 2026."

Financing • Parkinson's Disease

Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms (clinicaltrials.gov) - P=N/A | N=92 | Completed | Sponsor: Abyss Ingredients | Recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms (clinicaltrials.gov) - P=N/A | N=108 | Recruiting | Sponsor: Abyss Ingredients

New trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Prolyl Endopeptidase modulation by ACT-02 prevents a-synuclein aggregation in a transgenic model of Parkinson disease (EAN 2022) - "PREP modulation by ACT-02 improves PD neurodegeneration via multiple mechanisms in the Line 61 a-syn transgenic model, and therefore has potential therapeutic value for disease modifying treatment of PD."

CNS Disorders • Movement Disorders • Parkinson's Disease • THY1

New Spanish firm Accure Therapeutics launched (The Pharma Letter) - "...Accure Therapeutics, a new pharma R&D player in the central nervous system (CNS) field, announces its launch with a Series A round of funding totaling 7.6 million euros ($8.1 million). The funding round was led by Alta Life Sciences and supported by the Center for Technological and Industrial Development (CDTI)....The company will start work on three distinct new medicine programs focused on innovative targets....The initial assets, ACT-01 ready for testing in a clinical Phase II study and both ACT-02 and ACT-03 in preclinical experiments, have been sourced from two Spanish R&D companies (Bionure and Iproteos) and academic research centers with a strong scientific background in neurobiology."

Financing • New P2 trial • Preclinical • CNS Disorders